MannKind Corporation Stock

Equities

MNKD

US56400P7069

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:04 2024-05-31 pm EDT 5-day change 1st Jan Change
4.675 USD +3.89% Intraday chart for MannKind Corporation -2.20% +28.43%
Sales 2024 * 272M Sales 2025 * 319M Capitalization 1.27B
Net income 2024 * 35M Net income 2025 * 70M EV / Sales 2024 * 3.76 x
Net cash position 2024 * 248M Net cash position 2025 * 273M EV / Sales 2025 * 3.14 x
P/E ratio 2024 *
40.6 x
P/E ratio 2025 *
21.2 x
Employees 413
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.96%
More Fundamentals * Assessed data
Dynamic Chart
MannKind Agrees to Cross License Deal With Pulmatrix MT
Pulmatrix, Inc. Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation CI
Transcript : MannKind Corporation, Q1 2024 Earnings Call, May 08, 2024
Earnings Flash (MNKD) MANNKIND Posts Q1 EPS $0.05 MT
Earnings Flash (MNKD) MANNKIND Reports Q1 Revenue $66.3M, vs. Street Est of $60.6M MT
MannKind Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
MannKind Receives FDA Fast Track Designation for its Potential Lung Disease Treatment MT
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial Lung Disease CI
MannKind Corporation to Proceed with Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases CI
MannKind Gets FDA Approval to Begin Phase 3 Trial of Lung Disease Treatment MT
MannKind Gets FDA Clearance for Clofazimine IND Application DJ
MannKind Corporation Announces IND Clearance from U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial Lung Disease CI
MannKind CFO Binder to Retire in April, Names New CFO MT
MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024 CI
MannKind Corporation Appoints Steven B. Binder as Executive Vice President, Special Projects CI
More news
1 day+3.89%
1 week-2.20%
Current month+0.11%
1 month+13.75%
3 months+13.75%
6 months+29.14%
Current year+28.43%
More quotes
1 week
4.41
Extreme 4.405
4.85
1 month
4.17
Extreme 4.165
4.89
Current year
3.17
Extreme 3.17
5.40
1 year
3.17
Extreme 3.17
5.75
3 years
2.49
Extreme 2.49
5.75
5 years
0.80
Extreme 0.8
6.25
10 years
0.67
Extreme 0.6662
57.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 16-03-13
Chief Tech/Sci/R&D Officer 57 22-09-30
Chief Tech/Sci/R&D Officer - 20-08-30
Members of the board TitleAgeSince
Director/Board Member 55 18-11-26
Director/Board Member 69 19-12-31
Director/Board Member 80 03-09-30
More insiders
Date Price Change Volume
24-05-31 4.67 +3.78% 2,484,452
24-05-30 4.5 -0.66% 1,983,878
24-05-29 4.53 -2.16% 2,276,815
24-05-28 4.63 -3.14% 1,966,483
24-05-24 4.78 -0.83% 1,262,379

Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT

More quotes
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.67 USD
Average target price
7.083 USD
Spread / Average Target
+51.68%
Consensus